- ARRY-424704, ARRY-704
-
- $1.10 / 1g
-
2024-04-17
- CAS:869357-68-6
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
- ARRY-424704, ARRY-704
-
- $0.00 / 1KG
-
2022-10-14
- CAS:869357-68-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
- ARRY-424704, ARRY-704
-
- $1.10 / 1g
-
2021-10-22
- CAS:869357-68-6
- Min. Order: 1g
- Purity: 99.00%
- Supply Ability: 100 Tons Min
|
| | ARRY-424704, ARRY-704 Basic information |
| Product Name: | ARRY-424704, ARRY-704 | | Synonyms: | ARRY-424704, ARRY-704;AZD8330;2-(2-Fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide;ARRY424704;ARRY-424704;ARRY704;ARRY-704;AZD8330/ARRY-424704/arry-704/AZD8330/AZD-8330 | | CAS: | 869357-68-6 | | MF: | C16H17FIN3O4 | | MW: | 461.23 | | EINECS: | 642-441-7 | | Product Categories: | Inhibitors;MAPK | | Mol File: | 869357-68-6.mol |  |
| | ARRY-424704, ARRY-704 Chemical Properties |
| density | 1.732 | | storage temp. | Store at -20°C | | solubility | ≥23.05 mg/mL in DMSO; insoluble in H2O; ≥46.1 mg/mL in EtOH | | form | solid | | pka | 14.31±0.10(Predicted) |
| | ARRY-424704, ARRY-704 Usage And Synthesis |
| Description | AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells. AZD 8330 is orally bioavailable, inhibits ERK phosphorylation in vivo, and reduces tumor growth in a Calu-6 nude rat xenograft model. | | Uses | AZD8330 is an orally active and selective MEK inhibitor. | | Definition | ChEBI: 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide is a pyridinecarboxamide. It is functionally related to a nicotinamide. | | target | ERK phosphorylation | | references | 1. feng k, wang c, zhou h, yang j, dong l, zhou k, et al. [effect of erk1/2 inhibitor azd8330 on human burkitt's lymphoma cell line raji cells and its mechanism]. zhonghua xue ye xue za zhi 2015,36:148-152.2. cohen rb, aamdal s, nyakas m, cavallin m, green d, learoyd m, et al. a phase i dose-finding, safety and tolerability study of azd8330 in patients with advanced malignancies. eur j cancer 2013,49:1521-1529. |
| | ARRY-424704, ARRY-704 Preparation Products And Raw materials |
|